上海睿艴国际贸易有限公司成立于2018年8月，是专门从事健康产品事业的日资子公司。睿艴国际贸易的80%股份由上海睿星基因技术有限公司控股。上海睿星基因技术有限公司是以归国留学人员为核心，上海创业投资有限公司和上海张江高科技园区开发股份有限公司共同出资，后由GNI公司投资的新药开发企业。现注册资金人民币10800万元。目前公司雇员其中70%为科研人员，包括多名博士。GNI是一家从事基因组基础研究的初创公司发展到东京证券交易所主板上市的成熟的年轻制药公司。

Shanghai Rui Fu International Trade Co., Ltd. (Rui Fu) is the subsidiary company of Shanghai Genomics Inc. (SG) and takes full charge of Health Care Business from August 1, 2018., which is 80% controlled by SG. SG is a new drug development enterprise invested by GNI later, which was previously invested by Shanghai Venture Capital Co., Ltd. and Shanghai Zhangjiang Hi-tech Park Development Co., Ltd. with returned students as the core. The registered capital is 108MRMB. At present, 70% of the company's employees are researchers, including a number of Ph. D. GNI has evolved from a basic